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recent recommendations for epilepsy care in the elderly.
Research is needed to identify why new patients receive
phenobarbital. The vast use of phenytoin suggests
research evaluating the impact of phenytoin and other
AEDs on the elderly in actual practice may be needed to
facilitate adoption of recent clinical recommendations.
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OBJECTIVES: Allergies and many sedating over-the-
counter (OTC) allergy medications have been shown to
have a signiﬁcant and negative impact on lost productive
time at work. We examine the impact of an allergy
program designed to reduce sedating allergy medication
use and its impact on employee-reported lost productiv-
ity within a large southern California medical group.
METHODS: A baseline questionnaire designed to
measure allergy symptoms, severity, treatment strategies,
and disease burden was distributed to 712 employees in
November 2001 with a follow-up questionnaire sent in
November 2002. We calculated change in self-reported
productive time lost due to allergy related full and partial
missed days, and presenteeism (lower productive time
while at work) from merged baseline and follow-up data.
Interventions included recommended treatment guide-
lines that were developed and distributed to all physicians
and clinics. Employees were encouraged to discuss their
allergy medications and treatment strategies with their
physicians and were provided access to a corporate
Intranet site for additional allergy-speciﬁc information.
RESULTS: Response rates of 85% and 58% were
achieved at baseline and 1-year follow-up. In addition,
59% of allergic employees participated in the program
with 44% reporting visiting a doctor and 28% using the
Intranet. Sedating OTC medication use dropped from
38% to 21% (p < .0001). Allergy speciﬁc average
monthly hours missed decreased due to presenteeism (7.2
hours; p < .0001) and overall (5.5 hours; p = .0076) per
allergic employee. Average monthly hours missed
increased due to full days (1.1 hour) and partial days (.06
hour) but were not statistically signiﬁcant. CONCLU-
SIONS: While allergies account for a signiﬁcant number
of lost productive work hours, an allergy program can
successfully reduce sedating medication use, consequent
disease burden, and lost productive work time. Projected
annually, appropriate treatment of allergy symptoms
resulted in cost savings of approximately $1254 per aller-
gic employee.
EP2
COST ANALYSIS OF HEPATITIS C VIRUS (HCV)
INFECTION:AN EMPLOYER’S PERSPECTIVE
Duh MS1, Moyneur É2,Van Audenrode M3, Mody SH4,
Piech CT4
1Analysis Group/Economics, Boston, MA, USA; 2Analysis
Group/Economics, Montreal, QC, Canada; 3Université Laval,
Québec, QC, Canada; 4Ortho Biotech Products, LP,
Bridgewater, NJ, USA
OBJECTIVE: With improvements in therapy, HCV
disease progression can be better controlled and a greater
number of infected patients are able to remain in the
workforce. This analysis quantiﬁes the incremental direct
(medical, drugs) and indirect (absenteeism, disability)
costs of HCV from an employer’s perspective.
METHODS: Based on eligibility, medical, pharmacy and
disability claims data from seven major US employers
covering January 1, 1998 through June 30, 2001, we
identiﬁed 833 HCV infected patients having at least 2
claims with a HCV ICD-9 diagnosis code less than 90
days apart, ribavirin and interferon combination therapy,
a conﬁrmatory HCV lab test followed by a HCV diag-
nosis, or a HCV diagnosis coupled with non-alcoholic 
cirrhosis, hepatocarcinoma, liver transplantation, or
cryoglobulinemia. A 10% random sample of 148,166
uninfected individuals was chosen as controls. Employer
costs resulted from direct medical costs and employee
productivity loss. A tobit regression, which corrects for
non-normality of costs, included controls for age, gender,
health plan, location, alcohol abuse, HIV status, and
illicit drug use. RESULTS: The unadjusted ratio of mean
direct costs for HCV infected patients compared to unin-
fected patients was 7.9 :1 ($857.4 vs. $108.1 per patient-
month, p < .01). The ratio for indirect costs was 4.0 :1
($88.7 vs. $22.3 per patient-month, p < .01). After con-
trolling for confounding factors, the ratios were 5.6 :1
(95% CI: 5.6–5.7) for direct costs, and 8.1:1 (95% CI:
7.9–8.4) for indirect costs. Regressions on sub-categories
yielded costs ratios for inpatient care, outpatient care,
prescription drugs, absenteeism, and disability (short 
and long-term) of 5.3 :1 (95% CI: 5.2–5.4), 5.0:1 (95%
CI: 5.0–5.1), 7.5:1 (95% CI: 7.4–7.5), 5.5:1 (95% 
CI: 5.4–5.7), and 10.0 :1 (95% CI: 9.2–10.8), respec-
tively. CONCLUSION: Both the unadjusted and adjusted
cost ratios for HCV infected patients compared to unin-
fected patients indicate that infection results in statisti-
cally signiﬁcant increases in both direct and indirect costs
to the employers.
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